AGL 7.94 Decreased By ▼ -0.06 (-0.75%)
ANL 11.30 Decreased By ▼ -0.02 (-0.18%)
AVN 83.90 Increased By ▲ 0.45 (0.54%)
BOP 6.15 Increased By ▲ 0.30 (5.13%)
CNERGY 5.72 Decreased By ▼ -0.13 (-2.22%)
EFERT 80.25 Increased By ▲ 0.15 (0.19%)
EPCL 65.35 Decreased By ▼ -1.94 (-2.88%)
FCCL 15.10 Decreased By ▼ -0.10 (-0.66%)
FFL 7.16 Increased By ▲ 0.12 (1.7%)
FLYNG 7.87 Increased By ▲ 0.10 (1.29%)
GGGL 11.81 Decreased By ▼ -0.09 (-0.76%)
GGL 17.53 Decreased By ▼ -0.12 (-0.68%)
GTECH 9.39 Increased By ▲ 0.21 (2.29%)
HUMNL 7.27 Increased By ▲ 0.07 (0.97%)
KEL 3.50 No Change ▼ 0.00 (0%)
LOTCHEM 30.74 Decreased By ▼ -0.21 (-0.68%)
MLCF 28.36 Decreased By ▼ -0.16 (-0.56%)
OGDC 85.19 Decreased By ▼ -0.01 (-0.01%)
PAEL 17.10 Decreased By ▼ -0.01 (-0.06%)
PIBTL 6.15 No Change ▼ 0.00 (0%)
PRL 19.52 Decreased By ▼ -0.32 (-1.61%)
SILK 1.30 Increased By ▲ 0.01 (0.78%)
TELE 12.11 Increased By ▲ 0.06 (0.5%)
TPL 9.10 Decreased By ▼ -0.06 (-0.66%)
TPLP 20.30 Increased By ▲ 0.11 (0.54%)
TREET 27.10 No Change ▼ 0.00 (0%)
TRG 97.45 Increased By ▲ 0.15 (0.15%)
UNITY 22.91 Increased By ▲ 0.08 (0.35%)
WAVES 13.21 Decreased By ▼ -0.08 (-0.6%)
WTL 1.48 Increased By ▲ 0.03 (2.07%)
BR100 4,358 Decreased By -3.1 (-0.07%)
BR30 16,031 Increased By 21.9 (0.14%)
KSE100 43,463 Decreased By -18.9 (-0.04%)
KSE30 16,464 Decreased By -11.8 (-0.07%)
World

BioNTech expects vaccine trial results for babies by September

  • He added it takes about four to six weeks to evaluate the data.
Published April 29, 2021

BERLIN: BioNTech expects results by September from trials testing the COVID-19 vaccine that it and Pfizer have developed in babies as young as six months old, German magazine Spiegel cited the company's CEO as saying.

"In July, the first results could be available for the five to 12 year olds, in September for the younger children," BioNTech Chief Executive Ugur Sahin told Spiegel.

He added it takes about four to six weeks to evaluate the data.

"If all goes well, as soon as the data is evaluated, we will be able to submit the application for approval of the vaccine for all children in the respective age group in different countries," he said.

BioNTech and Pfizer asked US regulators this month to approve emergency use of their vaccine for adolescents aged 12 to 15.

Sahin was quoted by Spiegel as saying the company was "in the final stages before submission" to European regulators for children aged 12 and older.

A trial published at the end of March found the companies' COVID-19 vaccine was safe, effective and produces robust antibody responses in adolescents.

The Pfizer/BioNTech two-shot vaccine is already authorized for use in those aged 16 and above.

Young people are less likely to suffer severe cases of COVID-19 and more likely to have asymptomatic infection, allowing them to unwittingly transmit COVID-19 to others.

Comments

Comments are closed.